Guadecitabine Extension Study
Condition(s):Acute Myeloid Leukemia; Myeloid Dysplastic SyndromeLast Updated:April 26, 2023Terminated
Hide Studies Not Open or Pending
Condition(s):Acute Myeloid Leukemia; Myeloid Dysplastic SyndromeLast Updated:April 26, 2023Terminated
Condition(s):Acute Myeloid LeukemiaLast Updated:May 25, 2023Completed
Condition(s):Myelodysplastic Syndromes; Acute Myeloid LeukemiaLast Updated:November 15, 2018Unknown status
Condition(s):Germ Cell Tumor; Testis Cancer; Testicular CancerLast Updated:September 23, 2020Completed
Condition(s):Paraganglioma; Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Renal Neoplasms; PheochromocytomaLast Updated:April 5, 2022Terminated
Condition(s):Myelodysplastic Syndromes; Leukemia, Myelomonocytic, ChronicLast Updated:May 18, 2023Completed
Condition(s):High Risk Myelodysplastic SyndromeLast Updated:November 18, 2023Active, not recruiting
Condition(s):Small Cell Lung Cancer; Extensive-stage Small Cell Lung CancerLast Updated:December 20, 2023Completed
Condition(s):Advanced Kidney Cancer; Kidney Cancer; Clear Cell Renal Cell CarcinomaLast Updated:February 17, 2022Active, not recruiting
Condition(s):Colorectal Adenocarcinoma; CpG Island Methylator Phenotype; Metastatic Microsatellite Stable Colorectal Carcinoma; Refractory Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8Last Updated:April 5, 2021Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.